title: [Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction].
abstract: OBJECTIVE
  To explore patient and nurse satisfaction, compliance with best practice, technical feasibility and safety of home infusion of a bisphosphonate.
  
  
  METHODS
  Prospective 1-year survey of home zoledronic acid therapy (4 mg, 15-min intravenous, every three to four weeks) in patients with bone metastases secondary to a solid malignancy. A physician questionnaire, nurse satisfaction/feasibility questionnaire and patient satisfaction questionnaire were administered.
  
  
  RESULTS
  Physician participation rate: 56.5% (87/154); 818 patients included; 381 predominantly community nurses; 763/788 case report forms meeting inclusion criteria.
  
  
  METHODS
  median age, 68 years (30-95); M/F, 40/60; ECOG-PS 0 or 1, 78.6%; primary tumour site: breast (55.2%), prostate (28.4%), lung (7.2%), other (9.4%). Nurse satisfaction rates: 90.9% (organization of home ZOL therapy); 96.7% (ease of infusion); 97.5% (patient-nurse relationship); 73% (relationship with hospital staff). Patient satisfaction rates: 95.3% overall; 57.6% (quality of the nurse-patient relationship); 68.8% (less travel/waiting); 52.9% (consideration for home environment). Treatment tolerance: 33.63% (discontinuation due to adverse events); 0.6% (osteonecrosis of the jaw); 0.2% fractures. Practitioner compliance with best practice: 76.7% to 83.7% (recommended and/or tolerated dosage), 73% (dental hygiene checks at inclusion; 48 to 56% thereafter); 66% (pre-infusion hydration); often undocumented for calcium/vitamin D supplementation.
  
  
  CONCLUSIONS
  Home zoledronic acid treatment was well tolerated. There was a very high level of both patient and nurse satisfaction with home therapy. However, better compliance with best practice should be encouraged.
authors.affiliation: Hôpital Foch, service d'urologie, Université de Versailles-Saint-Quentin-en-Yvelines, 40, rue Worth, BP 36, 92151 Suresnes cedex, France. t.lebret@hopital-foch.org
authors.forename: Thierry
authors.initials: T
authors.lastname: Lebret
authors.forename: Jean-Loup
authors.initials: JL
authors.lastname: Mouysset
authors.forename: Alain
authors.initials: A
authors.lastname: Lortholary
authors.forename: Claude El
authors.initials: CE
authors.lastname: Kouri
authors.forename: Laurent
authors.initials: L
authors.lastname: Bastit
authors.forename: Meryem
authors.initials: M
authors.lastname: Ktiouet
authors.forename: Slimane
authors.initials: S
authors.lastname: Khemaies
authors.forename: Xavier
authors.initials: X
authors.lastname: Murraciole
authors.forename: Stéphane
authors.initials: S
authors.lastname: Guérif
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019985:Benchmarking; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000209:etiology; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000523:psychology / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D005240:Feasibility Studies; D005260:Female; D018718:Home Infusion Therapy; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009723:Nurse-Patient Relations; D009740:Nursing Staff / Q000523:psychology; D010349:Patient Compliance; D017060:Patient Satisfaction; D010549:Personal Satisfaction; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000473:pathology; D011795:Surveys and Questionnaires; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid
keywords: bone metastases; home based treatment; solid tumour; zoledronic acid